3-Amino-2-fluoropyridine | CAS:1597-33-7

We serve 3-Amino-2-fluoropyridine CAS:1597-33-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Amino-2-fluoropyridine

Chemical Name: 3-Amino-2-fluoropyridine
CAS.NO:1597-33-7
Synonyms:2-fluoropyridin-3-amine;
Molecular Formula:C5H5FN2
Molecular Weight:112.10500
 
Physical and Chemical Properties:
Density:1.3±0.1 g/cm3
Melting point:/
Boiling point:243.2±20.0 °C at 760 mmHg
Flash point:100.9±21.8 °C
Index of Refraction:1.554
 
Specification:
Appearance:Yellow liquid
Purity:≥99.0%
 
Packing:25kg/drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:  used in the pharmaceutical intermediate



Contact us for information like 3-Amino-2-fluoropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-fluoropyridin-3-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Amino-2-fluoropyridine Use and application,2-fluoropyridin-3-amine technical grade,usp/ep/jp grade.


Related News: Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.(S)-N-(4-(2,5-Dioxooxazolidin-4-yl)butyl)-2,2,2-trifluoroacetamide manufacturer The program caused the price of some drugs to plunge more than 90% when it was introduced last year in some cities, state news agency Xinhua said.3-Bromo-4-fluorotoluene supplier The CTSuccess service uses Catalent’s proprietary StartScoreTM evaluation tool to calculate the complexity of a potential clinical project across more than a dozen specific and objective study characteristics.1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.Villages and cities in China have resorted to flying drones with speakers to patrol streets and scold people not wearing masks in public amid the coronavirus outbreak, according to Chinese state media.